Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable safety profile

Haematologica. 2025 Feb 1;110(2):488-492. doi: 10.3324/haematol.2024.285380.
No abstract available

Grants and funding

Funding: This research was funded by the Menarini Group, New York, NY, USA.